Table 1

Baseline and follow-up characteristics of post-stroke survivors (n = 435)*

CharacteristicCCR5-Δ32 noncarriers (n = 365)CCR5-Δ32 carriers (n = 70)†p value
Age, yr66.7 ± 9.768.9 ± 9.90.08
Male232 (63.6)38 (54.3)0.030
Education, yr12.7 ± 3.814.7 ± 3.8< 0.001
Body mass index, kg/m227.1 ± 4.727.4 ± 3.10.49
Ethnicity, Ashkenazi189 (51.8)60 (85.7)< 0.001
Current smoker85 (23.3)17 (24.3)0.69
Diabetes mellitus108 (29.6)22 (31.4)0.76
Dyslipidemia201 (55.1)38 (54.3)0.90
Hypertension224 (61.4)41 (58.6)0.66
Ischemic heart disease64 (17.5)15 (21.4)0.44
Framingham Risk Score for stroke11.3 ± 5.512.4 ± 5.80.22
APOE ɛ4 allele59 (16.2)11 (15.7)0.95
NIHSS at hospital admission, median (interquartile range)2.00 (0.00–4.00)2.00 (0.00–3.00)0.005
C-reactive protein at hospital admission, mg/L8.0 ± 16.04.4 ± 6.00.003
Transient ischemic attack109 (29.9)24 (34.3)0.46
Geriatric Depression Scale score, median (interquartile range)
 At hospital admission2.00 (1.00–4.00)2.00 (0.00–3.00)0.035
 6 months post-stroke2.00 (0.00–4.00)1.00 (0.00–3.00)< 0.001
 12 months post-stroke2.00 (0.00–4.00)1.00 (0.00–2.00)< 0.001
 24 months post-stroke2.00 (0.00–4.00)1.00 (0.00–2.25)0.006
Brain MRI parameters
 No MRI performed86 (23.6)14 (20)0.52
 Infarct type‡
  No infarct83 (29.7)19 (33.9)0.69
  Cortical61 (21.9)22 (39.3)0.005
  Subcortical101 (36.2)11 (19.6)0.07
  Subtentorial34 (12.2)4 (7.1)0.13
 Ischemic lesion volume, mm37459.1 ± 1202.87372.4 ± 1170.60.65
 Intracranial volume, mm31 458 197.3 ± 168 6081 422 139.9 ± 195 470.80.19
 Total white matter volume, mm3444 438 ± 64 184.7442 681.9 ± 69 646.40.86
 Total grey matter volume, mm3578 935.1 ± 60 663564 562.1 ± 66 959.70.14
 Microbleed, lobar34 (9.3)10 (14.3)0.21
 Microbleed, deep15 (4.1)2 (2.9)0.62
 Lacunes112 (30.7)21 (30.0)0.91
 Enlarged perivascular spaces258 (70.7)54 (77.1)0.27

  • NIHSS = National Institutes of Health Stroke Scale.

  • ↵* Values are mean ± standard deviation or n (%), unless otherwise indicated.

  • ↵† 66 heterozygote, 4 homozygote.

  • ↵‡ Percentages based on only patients who had an MRI (n = 279 for CCR5-Δ32 noncarriers; n = 56 for CCR5-Δ32 carriers).